Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magali Traskine

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Journal of Computational Biology : a Journal of Computational Molecular Cell Biology|May 13, 2009
A regularized method for selecting nested groups of relevant genes from microarray dataChristine De Mol, Sofia Mosci, Magali Traskine, et al.
Human Vaccines & Immunotherapeutics|November 11, 2020
Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable <i>Haemophilus influenzae</i> protein D-conjugate vaccine in healthy toddlers: results from a phase I, randomized trialMichael Horn, Ulrich Behre, Magali Traskine, et al.
Vaccine|April 5, 2014
Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trialRoman Prymula, Petr Pazdiora, Magali Traskine, et al.
Vaccine|May 23, 2018
Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized studyGhassan Dbaibo, Juan Carlos Tinoco Favila, Magali Traskine, et al.
The Pediatric Infectious Disease Journal|May 17, 2011
Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of lifeSven Arne Silfverdal, Helena Skerlikova, Maria Zanova, et al.
Vaccine|March 11, 2014
Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical studyGeert Leroux-Roels, Cathy Maes, Fien De Boever, et al.
Plos One|September 19, 2008
Characterization of the p53 response to oncogene-induced senescenceLidia Ruiz, Magali Traskine, Irene Ferrer, et al.
Vaccine|July 22, 2017
Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infantsRoman Prymula, Leszek Szenborn, Sven-Arne Silfverdal, et al.
Vaccine|December 27, 2017
Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized studyKhalequ Zaman, Sheikh Farzana Zaman, Farzana Zaman, et al.
The Pediatric Infectious Disease Journal|August 19, 2015
Effectiveness of the Ten-valent Pneumococcal Conjugate Vaccine Against Tympanostomy Tube Placements in a Cluster-randomized TrialArto A Palmu, Jukka Jokinen, Heta Nieminen, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Journal of Computational Biology : a Journal of Computational Molecular Cell Biology|May 13, 2009
A regularized method for selecting nested groups of relevant genes from microarray dataChristine De Mol, Sofia Mosci, Magali Traskine, et al.
Human Vaccines & Immunotherapeutics|November 11, 2020
Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable <i>Haemophilus influenzae</i> protein D-conjugate vaccine in healthy toddlers: results from a phase I, randomized trialMichael Horn, Ulrich Behre, Magali Traskine, et al.
Vaccine|April 5, 2014
Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trialRoman Prymula, Petr Pazdiora, Magali Traskine, et al.
Vaccine|May 23, 2018
Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized studyGhassan Dbaibo, Juan Carlos Tinoco Favila, Magali Traskine, et al.
The Pediatric Infectious Disease Journal|May 17, 2011
Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of lifeSven Arne Silfverdal, Helena Skerlikova, Maria Zanova, et al.
Vaccine|March 11, 2014
Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical studyGeert Leroux-Roels, Cathy Maes, Fien De Boever, et al.
Plos One|September 19, 2008
Characterization of the p53 response to oncogene-induced senescenceLidia Ruiz, Magali Traskine, Irene Ferrer, et al.
Vaccine|July 22, 2017
Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infantsRoman Prymula, Leszek Szenborn, Sven-Arne Silfverdal, et al.
Vaccine|December 27, 2017
Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized studyKhalequ Zaman, Sheikh Farzana Zaman, Farzana Zaman, et al.
The Pediatric Infectious Disease Journal|August 19, 2015
Effectiveness of the Ten-valent Pneumococcal Conjugate Vaccine Against Tympanostomy Tube Placements in a Cluster-randomized TrialArto A Palmu, Jukka Jokinen, Heta Nieminen, et al.
Pageof 2